Matthias Schroff

878 citations

39 papers · 685 indexed · h-index 16

Co-authors: Burghardt Wittig Claas Junghans Manuel Schmidt Christiane Kleuss Ingo G.H. Schmidt‐Wolf Frank Schakowski Marcus Gorschlüter Tilman Sauerbruch
Topics: Immunotherapy and Immune Responses (15 papers)RNA Interference and Gene Delivery (10 papers)Cancer Research and Treatments (9 papers)
Cited by: Immunology Virology Genetics
Journals: Journal of Clinical Oncology PLoS ONE Journal of Virology
Partner nations: Germany United States United Kingdom

In The Last Decade

Matthias Schroff

35 papers receiving 649 citations

Peers

Countries citing papers authored by Matthias Schroff

Since Specialization

Citations

This map shows the geographic impact of Matthias Schroff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias Schroff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias Schroff more than expected).

Fields of papers citing papers by Matthias Schroff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthias Schroff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias Schroff. The network helps show where Matthias Schroff may publish in the future.

Co-authorship network of co-authors of Matthias Schroff

This figure shows the co-authorship network connecting the top 25 collaborators of Matthias Schroff. A scholar is included among the top collaborators of Matthias Schroff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthias Schroff. Matthias Schroff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist 2016 ·Molecular Therapy — Oncolytics ·(unknown),Manuel Schmidt,(unknown),(unknown),Matthias Schroff,Burghardt Wittig	5
2	Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703 2015 ·Nucleic Acid Therapeutics ·Manuel Schmidt,Nicole Hagner,Alberto Marco,(unknown),Matthias Schroff,Burghardt Wittig	38
3	Safety, pharmacokinetics and pharmacodynamics from a clinical trial with healthy volunteers using the immunotherapeutic TLR-9 agonist MGN1703 2015 ·Annals of Oncology ·(unknown),Manuel Schmidt,(unknown),(unknown),(unknown),Matthias Schroff,(unknown)	1
4	Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine 2015 ·Gene Therapy ·(unknown),Karin Seifert,(unknown),(unknown),Carl E. Hock,(unknown),Francisco J. Salguero,Matthias Schroff,S. L. Croft,(unknown)	18
5	Cationic Lipid-Formulated DNA Vaccine against Hepatitis B Virus: Immunogenicity of MIDGE-Th1 Vectors Encoding Small and Large Surface Antigen in Comparison to a Licensed Protein Vaccine 2014 ·PLoS ONE ·(unknown),(unknown),(unknown),(unknown),(unknown),Eduard G. Talman,Matthias Schroff,Christiane Kleuss,Marcel H.J. Ruiters,(unknown)	15
6	Combination of MIDGE-Th1 DNA vaccines with the cationic lipid SAINT-18: Studies on formulation, biodistribution and vector clearance 2014 ·Vaccine ·(unknown),(unknown),(unknown),Eduard G. Talman,(unknown),Matthias Schroff,Christiane Kleuss,Marcel H.J. Ruiters,(unknown)	6
7	Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours 2014 ·European Journal of Cancer ·Martin R. Weihrauch,Heike Richly,Michael S. von Bergwelt‐Baildon,H. Becker,Manuel Schmidt,Ulrich Hacker,Alexander Shimabukuro‐Vornhagen,Udo Holtick,(unknown),Matthias Schroff,Burghardt Wittig,M. E. Scheulen	54
8	Aset Study: Final Results of Patients with Locally Recurrent or Metastatic Renal Cell Carcinoma (Rcc) Treated with Mgn1601 2014 ·Annals of Oncology ·Viktor Grünwald,S. Weikert,I G Schmidt-Wolf,Stefan Hauser,Ahmed Magheli,(unknown),Matthias Schroff,Manuel Schmidt,(unknown)	2
9	Genuine Immunomodulation With dSLIM 2014 ·Molecular Therapy — Nucleic Acids ·(unknown),Christiane Kleuss,Matthias Schroff,Burghardt Wittig	19
10	New safety and efficacy data of the ongoing phase I/II study (ASET Study) with an allogeneic tumor vaccine and adjuvant in patients with metastatic renal cell carcinoma. 2012 ·Journal of Clinical Oncology ·Viktor Grünwald,Steffen Weikert,(unknown),Stefan Hauser,Marina Tschaika,(unknown),Matthias Schroff,Manuel Schmidt,Burghardt Wittig	0
11	Safety data of MGN1601, a tumor vaccine, made of allogeneic, transfected, and irradiated tumor cells in combination with an immunomodulator for the treatment of metastatic renal cell carcinoma. 2010 ·Journal of Clinical Oncology ·Manuel Schmidt,(unknown),Matthias Schroff,(unknown),Christiane Kleuss,Marina Tschaika,B. Wittig	1
12	Peripheral Non-Viral MIDGE Vector-Driven Delivery of β-Endorphin in Inflammatory Pain 2009 ·Molecular Pain ·Halina Machelska,Matthias Schroff,(unknown),Waltraud Binder,Nicolle Sitte,Shaaban A. Mousa,Heike L. Rittner,Alexander Brack,Dominika Łabuz,(unknown),Burghardt Wittig,Michael Schäfer,Christoph Stein	22
13	Minimal size MIDGE vectors improve transgene expression in vivo. 2007 ·PubMed ·Frank Schakowski,Marcus Gorschlüter,Peter Buttgereit,Angela Märten,Marie von Lilienfeld‐Toal,Claas Junghans,Matthias Schroff,(unknown),Carsten Ziske,John Strehl,Tilman Sauerbruch,Burghardt Wittig,Ingo G.H. Schmidt‐Wolf	31
14	Brief Communication: Stability and Catalytic Activity of Novel Circular DNAzymes 2006 ·Nucleosides Nucleotides & Nucleic Acids ·Georg Seifert,Tillmann Taube,(unknown),Hagen Graf Einsiedel,Sven Wellmann,Günter Henze,Karl Seeger,Matthias Schroff,Burghardt Wittig	3
15	Ballistic CTLA4 and IL-4 gene transfer into the lower lid prolongs orthotopic corneal graft survival in mice 2003 ·Graefe s Archive for Clinical and Experimental Ophthalmology ·(unknown),Jürgen Franke,Matthias Schroff,Claas Junghans,Burghardt Wittig,Friedrich Hoffmann	15
16	Up-regulation by feline interleukin-4 and down-regulation by feline interferon-gamma of major histocompatibility complex class II on cat B-lymphocytes 2002 ·Veterinary Immunology and Immunopathology ·Maria Alice Gomes-Keller,(unknown),Matthias Schroff,(unknown),Brian J. Willett,H. Lutz	6
17	Influence of ballistic gene transfer on antigen-presenting cells in murine corneas 2002 ·Graefe s Archive for Clinical and Experimental Ophthalmology ·(unknown),(unknown),Matthias Schroff,Burghardt Wittig,Friedrich Hoffmann	16
18	A Novel Minimal-Size Vector (MIDGE) Improves Transgene Expression in Colon Carcinoma Cells and Avoids Transfection of Undesired DNA 2001 ·Molecular Therapy ·Frank Schakowski,Marcus Gorschlüter,Claas Junghans,Matthias Schroff,Peter Buttgereit,Carsten Ziske,Björn Schöttker,(unknown),Tilman Sauerbruch,Burghardt Wittig,Ingo G.H. Schmidt‐Wolf	79
19	Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression 2000 ·AIDS ·Felicitas S. Boretti,Christian M. Leutenegger,Caroline N. Mislin,Regina Hofmann‐Lehmann,(unknown),Matthias Schroff,Claas Junghans,(unknown),(unknown),André Habel,J. Norman Flynn,André Aubert,Niels C. Pedersen,Burghardt Wittig,(unknown)	33
20	Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study 1998 ·British Journal of Cancer ·Peter Möller,Yuansheng Sun,Tomislav Dorbic,Selma Alijagic,(unknown),K Jurgovsky,Matthias Schroff,(unknown),B. Wittig,Dirk Schadendorf	69

About Matthias Schroff

Matthias Schroff is a scholar working on Biotechnology, Immunology and Oncology, having authored 39 papers that have together received 685 indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (15 papers), RNA Interference and Gene Delivery (10 papers) and Cancer Research and Treatments (9 papers). The work is most often cited by research in Immunology (316 citations), Virology (47 citations) and Genetics (190 citations). Matthias Schroff has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Burghardt Wittig, Claas Junghans, Manuel Schmidt, Christiane Kleuss, Ingo G.H. Schmidt‐Wolf, Frank Schakowski, Marcus Gorschlüter, Tilman Sauerbruch, Carsten Ziske and Peter Buttgereit. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Journal of Virology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact